RZLT
Rezolute, Inc. NASDAQ Listed Jan 14, 2013$3.09
Mkt Cap $295.7M
52w Low $1.07
19.4% of range
52w High $11.46
50d MA $3.14
200d MA $5.61
P/E (TTM)
-3.4x
EV/EBITDA
-3.1x
P/B
1.6x
Debt/Equity
0.0x
ROE
-63.6%
P/FCF
-4.9x
RSI (14)
—
ATR (14)
—
Beta
0.66
50d MA
$3.14
200d MA
$5.61
Avg Volume
2.5M
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
201 Redwood Shores Parkway · Redwood City, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -0.16 | -0.22 | -37.5% | 3.63 | -0.6% | +5.8% | +0.0% | -0.3% | -9.6% | -9.4% | — |
| Nov 6, 2025 | AMC | -0.27 | -0.18 | +33.3% | 9.60 | -1.6% | +12.1% | +3.8% | +4.6% | +4.2% | +3.5% | — |
| Sep 17, 2025 | AMC | -0.23 | -0.26 | -13.0% | 7.71 | -0.1% | +6.4% | -0.1% | +5.6% | +10.5% | +14.3% | — |
| May 13, 2025 | AMC | -0.22 | -0.27 | -22.7% | 3.67 | -4.9% | -4.9% | -3.0% | -2.7% | +3.5% | +7.6% | — |
| Feb 12, 2025 | AMC | -0.33 | -0.22 | +33.3% | 4.86 | +8.6% | -1.0% | -5.1% | -1.9% | -6.4% | -4.7% | — |
| Nov 7, 2024 | AMC | -0.35 | -0.22 | +37.1% | 5.72 | +2.1% | -2.4% | +4.2% | +1.7% | -1.4% | -2.1% | — |
| Sep 19, 2024 | AMC | -0.30 | -0.44 | -46.7% | 4.82 | +8.1% | +5.4% | -0.6% | -2.7% | +2.7% | +1.2% | — |
| May 15, 2024 | AMC | -0.34 | -0.34 | +0.0% | 2.65 | +0.0% | -3.4% | -0.4% | +6.0% | +13.2% | +6.0% | — |
| Feb 13, 2024 | AMC | -0.27 | -0.27 | +0.0% | 1.09 | -1.8% | +13.8% | +11.0% | +23.9% | +33.0% | +34.9% | — |
| Nov 13, 2023 | AMC | -0.33 | -0.28 | +15.2% | 0.85 | +6.7% | -7.4% | -12.0% | -5.2% | -4.1% | -12.1% | — |
| Sep 14, 2023 | AMC | -0.34 | -0.25 | +26.5% | 1.55 | +0.0% | +0.0% | -3.9% | -7.1% | -11.6% | -10.3% | — |
| May 11, 2023 | AMC | -0.31 | -0.30 | +3.2% | 2.03 | +2.5% | +2.0% | +2.5% | +3.0% | +5.9% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Wedbush | Upgrade | Neutral → Outperform | — | $2.69 | $2.90 | +7.8% | +18.2% | +20.8% | +11.2% | +5.9% | +13.4% |
| Jan 8 | BTIG | Maintains | Buy → Buy | — | $2.35 | $2.30 | -2.1% | +0.9% | +11.9% | +6.8% | +5.5% | +15.7% |
| Jan 8 | Wedbush | Maintains | Neutral → Neutral | — | $2.35 | $2.30 | -2.1% | +0.9% | +11.9% | +6.8% | +5.5% | +15.7% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.46 | +4.3% | +28.6% | +16.4% | +44.3% | +43.6% | +32.1% |
| Dec 12 | Guggenheim | Maintains | Buy → Buy | — | $1.40 | $1.46 | +4.3% | +28.6% | +16.4% | +44.3% | +43.6% | +32.1% |
| Nov 20 | BTIG | Maintains | Buy → Buy | — | $10.16 | $10.37 | +2.1% | -5.0% | -3.2% | -3.8% | -6.2% | -5.9% |
| Oct 29 | Citizens | Maintains | Market Outperform → Market Outperform | — | $9.49 | $9.75 | +2.7% | +0.4% | +3.5% | -1.8% | -4.1% | -6.2% |
| Sep 22 | Guggenheim | Maintains | Buy → Buy | — | $7.70 | $7.82 | +1.6% | +5.7% | +10.6% | +14.4% | +13.9% | +21.3% |
| Sep 19 | Maxim Group | Maintains | Buy → Buy | — | $8.20 | $8.45 | +3.0% | -6.1% | -0.7% | +3.9% | +7.4% | +7.0% |
| Sep 18 | BTIG | Maintains | Buy → Buy | — | $7.71 | $7.70 | -0.1% | +6.4% | -0.1% | +5.6% | +10.5% | +14.3% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.17 | $7.17 | +0.0% | +1.0% | +2.9% | +11.6% | +10.9% | +12.7% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.85 | $3.84 | -0.3% | -2.3% | +0.3% | -2.3% | +2.9% | +3.9% |
| Feb 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.86 | $5.28 | +8.6% | -1.0% | -5.1% | -1.9% | -6.4% | -4.7% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.86 | $5.28 | +8.6% | -1.0% | -5.1% | -1.9% | -6.4% | -4.7% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $4.91 | $4.95 | +0.8% | -1.4% | -2.6% | -1.0% | -2.0% | -6.1% |
| Feb 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.50 | $5.45 | -0.9% | +1.3% | -7.3% | -10.7% | -12.0% | -13.1% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.72 | $5.84 | +2.1% | -2.4% | +4.2% | +1.7% | -1.4% | -2.1% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.53 | +3.0% | -2.3% | -3.2% | -3.4% | -1.1% | -3.0% |
| Aug 6 | Maxim Group | Maintains | Buy → Buy | — | $4.40 | $4.53 | +3.0% | -2.3% | -3.2% | -3.4% | -1.1% | -3.0% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.00 | $3.62 | +20.7% | -6.3% | +2.0% | +18.7% | +23.0% | +37.7% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.65 | $2.65 | +0.0% | -3.4% | -0.4% | +6.0% | +13.2% | +6.0% |
| Apr 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.30 | $3.31 | +0.3% | +3.9% | +7.3% | -13.3% | -12.4% | -21.2% |
| Apr 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.24 | $3.35 | +3.4% | +1.9% | +5.9% | +9.3% | -11.7% | -10.8% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.86 | +3.3% | +0.6% | +5.6% | +11.1% | +8.3% | +6.7% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.09 | $1.07 | -1.8% | +13.8% | +11.0% | +23.9% | +33.0% | +34.9% |
| Nov 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.85 | $0.91 | +6.7% | -7.4% | -12.0% | -5.2% | -4.1% | -12.1% |
| Sep 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.49 | $1.48 | -0.7% | -3.4% | -8.1% | -6.7% | -4.7% | -10.7% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.50 | -3.2% | -3.9% | -7.1% | -11.6% | -10.3% | -8.4% |
| Sep 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.55 | $1.55 | +0.0% | +0.0% | -3.9% | -7.1% | -11.6% | -10.3% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.33 | +12.6% | -3.4% | -10.1% | -4.3% | -1.9% | +0.5% |
| Jun 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.07 | $2.33 | +12.6% | -3.4% | -10.1% | -4.3% | -1.9% | +0.5% |
| May 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.09 | $2.14 | +2.4% | +2.4% | -1.9% | -1.9% | +6.2% | +1.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.14 | +3.4% | +0.5% | +1.0% | +3.9% | +1.0% | +3.4% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | -7.5% | +2.0% | -5.0% | -4.0% | +2.5% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.69 | $2.68 | -0.4% | -4.5% | -7.4% | -6.7% | -2.6% | -11.5% |
| Feb 13 | JMP Securities | Maintains | Market Outperform → Outperform | — | $2.78 | $2.84 | +2.2% | -3.2% | -7.6% | -10.4% | -9.7% | -5.8% |
| Sep 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.35 | $2.25 | -4.3% | +7.7% | +14.9% | +14.9% | +15.3% | +21.7% |
| Sep 12 | Jefferies | Maintains | Buy → Buy | — | $2.27 | $2.65 | +16.7% | +3.5% | +11.5% | +18.9% | +18.9% | +19.4% |
| Jun 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.03 | $3.21 | +5.9% | +4.0% | +5.6% | +8.9% | +8.6% | +8.6% |
| Nov 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.36 | $5.20 | -3.0% | -1.9% | -5.2% | -13.2% | -17.5% | -21.5% |
| Nov 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.30 | $6.30 | +0.0% | -1.6% | -4.8% | -7.1% | -4.4% | -7.9% |
| Sep 8 | Roth Capital | Maintains | Buy → Buy | — | $9.74 | $9.55 | -2.0% | +1.6% | +2.7% | +9.9% | +0.1% | +1.5% |
| May 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.69 | $9.36 | +21.7% | +40.3% | +34.3% | +71.7% | +71.4% | +65.0% |
| May 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.45 | $6.96 | +7.9% | +15.3% | +19.2% | +67.3% | +60.2% | +104.7% |
| May 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.41 | $6.65 | +3.7% | +5.6% | +3.9% | +8.9% | +7.6% | +3.1% |
No insider trades available.
8-K
Unknown — 8-K Filing
RZLT's 8-K contains standard forward-looking statement disclaimers with no material updates, suggesting routine regulatory filing rather than significant corporate news affecting stock valuation.
Mar 24
8-K
Rezolute, Inc. -- 8-K Filing
Rezolute reported Q2 fiscal 2026 results and business updates for its late-stage hyperinsulinism treatment program, signaling progress in rare disease development.
Feb 12
Data updated apr 26, 2026 11:56pm
· Source: massive.com